Sun Pharma share price rises 2% on launch of ILUMYA in Japan

The company's wholly-owned Japanese subsidiary has launched ILUMYA Subcutaneous Injection 100 mg Syringe in Japan.

Buy Sun Pharmaceutical Industries; target of Rs 625: ICICI Direct

ICICI Direct is bullish on Sun Pharmaceutical Industries has recommended buy rating on the stock with a target price of Rs 625 in its research report dated August 02, 2020.

Reduce Sun Pharmaceutical Industries; target of Rs 479: Prabhudas Lilladher

Prabhudas Lilladher recommended reduce rating on Sun Pharmaceutical Industries with a target price of Rs 479 in its research report dated August 02, 2020.

Hold Sun Pharmaceutical Industries; target of Rs 479: Prabhudas Lilladher

Prabhudas Lilladher recommended Hold rating on Sun Pharmaceutical Industries with a target price of Rs 479 in its research report dated July 31, 2020.

Sun Pharma Consolidated June 2020 Net Sales at Rs 7,585.25 crore, down 9.42% Y-o-Y

Sun Pharma Standalone June 2020 Net Sales at Rs 2,963.04 crore, down 10.46% Y-o-Y

Sun Pharma share price hits 52-week high post June quarter earnings

Net profit before one-time loss stood at Rs 1,449.4 crore, which grew by 4.5 percent on year-on-year basis.

Sun Pharma posts Q1 loss Rs 1,655.6 crore on one-time loss, but operating numbers beat estimates

The company had reported a net profit of Rs 1,387.5 crore in the corresponding quarter a year ago.

Rakesh, Rekha Jhunjhunwala acquire 3.2% stake in Dishman, Vijay Kedia buys shares in Ramco in Q1 FY21

Life Insurance Corporation raised its stake in Godrej Industries to 3.87 percent in June quarter from 3.7 percent in the March quarter

Buy on dips, sell on rise best strategy till Nifty touches 11,300-11,500: Sumit Bilgaiyan

As FII inflows continue to remain strong, the liquidity remains healthy and hence sharper correction without a specific event trigger on domestic/global seems unlikely.

Buy Sun Pharmaceutical Industries; CMP of Rs 494.25: Equity99

Equity99 is bullish on Sun Pharmaceutical Industries has recommended buy rating on the stock with a CMP price of Rs 494.25 in its research report dated June 08, 2020.

Sun Pharma testing plant-based drug as potential COVID-19 treatment

AQCH is derived from tropical, climbing shrub cocculus hirsutus, which is used in Asia for its apparent medicinal properties.

Buy Sun Pharmaceutical Industries; target of Rs 540: ICICI Direct

ICICI Direct is bullish on Sun Pharmaceutical Industries has recommended buy rating on the stock with a target price of Rs 540 in its research report dated May 28, 2020.

Sun Pharma gains 5% on DGCI nod to initiate clinical trial of drug on COVID-19 patients

Nafamostat is approved in Japan for improvement of acute symptoms of pancreatitis and treatment of Disseminated Intravascular Coagulation (DIC).

Hold Sun Pharmaceutical Industries target of Rs 510: Sharekhan

Sharekhan recommended Hold rating on Sun Pharmaceutical Industries with a target price of Rs 510 in its research report dated May 27, 2020.

Hold Sun Pharmaceutical Industries; target of Rs 467: Prabhudas Lilladher

Prabhudas Lilladher recommended Hold rating on Sun Pharmaceutical Industries with a target price of Rs 467 in its research report dated May 28, 2020.

Buy Sun Pharmaceutical Industries; target of Rs 528: ICICI Securities

ICICI Securities is bullish on Sun Pharmaceutical Industries has recommended buy rating on the stock with a target price of Rs 528 in its research report dated May 27, 2020.

What should investors do with Sun Pharma: buy, sell or hold post Q4?

CLSA has maintained buy rating but cut target to Rs 560 from Rs 590 per share.

Sun Pharma Standalone March 2020 Net Sales at Rs 2,836.08 crore, up 11.13% Y-o-Y

Sun Pharma Consolidated March 2020 Net Sales at Rs 8,184.94 crore, up 14.25% Y-o-Y

Sun Pharma Q4 profit falls 37% to Rs 399.8 crore on one-time loss; revenue ahead of estimates

For the full year (FY20), Sun Pharma has reported a 41.3 percent growth in profit at Rs 3,764.93 crore and 13 percent increase in revenue at Rs 32,837.5 crore compared to previous year.

Sun Pharma Q4 profit, revenue expected to report healthy growth on low base

On the operating front, earnings before interest, tax, depreciation and amortisation (EBITDA) is expected to rise around 60 percent and margin may expand by more than 650 basis points YoY.

Hold Sun Pharmaceutical Industries; target of Rs 436: Prabhudas Lilladher

Prabhudas Lilladher recommended hold rating on Sun Pharmaceutical Industries with a target price of Rs 436 in its research report dated May 21, 2020.

Pharma index up 45% from March lows; CLSA says earnings momentum to continue, raises targets

The Nifty Pharma index gained half a percent on May 7, taking gains to around 45 percent since March 23.

Sun Pharma share falls 7% on USFDA red flag, but pares all losses

CLSA reiterated buy rating on the stock, though it slashed price target Rs 520 (from Rs 540 per share) on expected lower earnings.